Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14617040 | 1.00 | DGAT1 (0.58) | DGAT1SOAT1 | |
| SCHEMBL180850 | 1.00 | DGAT1 (0.58) | DGAT1SOAT1 | |
| SCHEMBL13664083 | 1.00 | DGAT1 (0.58) | DGAT1SOAT1 | |
| SCHEMBL14617041 | 0.91 | DGAT1 (0.52) | DGAT1SOAT1 | |
| SCHEMBL16546764 | 0.91 | DGAT1 (0.52) | DGAT1SOAT1 | |
| SCHEMBL180985 | 0.91 | DGAT1 (0.52) | DGAT1SOAT1 | |
| SCHEMBL180704 | 0.89 | DGAT1 (0.55) | DGAT1SOAT1 | |
| SCHEMBL180572 | 0.89 | MEN1 (0.57) | DGAT1SOAT1 | |
| SCHEMBL180833 | 0.89 | DGAT1 (0.52) | DGAT1SOAT1 | |
| SCHEMBL180467 | 0.88 | DGAT1 (0.53) | DGAT1SOAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150065517-A1 | NEW COMPOUNDS | NOVARTIS AG (CH) | 2015-03-05 | — | — | US | disclosed |
| US-20150065517-A1 | NEW COMPOUNDS | NOVARTIS AG (CH) | 2015-03-05 | — | — | US | disclosed |
| EP-2418202-B1 | (4-[4-[5-(substituted amino)-pyridin-2-yl]phenyl]-cyclohexyl)-acetic acid derivatives as DGAT inhibitors | NOVARTIS AG (CH) | 2014-01-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065517-A1 | NEW COMPOUNDS | DGAT1, DGAT2, GBA1 | DGAT1 1/4885SOAT1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.